Review Article
Commercial Dengue Rapid Diagnostic Tests for Point-of-Care Application: Recent Evaluations and Future Needs?
Table 2
Description of selected recent diagnostic assessments of dengue IgM, IgA, and IgG antibody RDTs.
| Assay | Study | Year | Location | Sample timing | Reference comparator | Antibody target | Sensitivity (95% CI) | Specificity (95% CI) |
| SD Bioline Dengue IgM (1st Generation) | Blacksell et al. [6]. | 2006 | Thailand | Admission | AFRIMS MAC and GAC-ELISA paired samples | IgM | 21.8 (17.4–26.7) | 98.8 (95.7–99.9) |
Nga et al. [32] | 2007 | Vietnam | 3 weeks illness | Focus IgM/IgG ELISA | IgM | 10.6 (6.0–18.0) | 99.0 (94.3–99.8) | IgG | 90.4 (84.6–94.2) | 88.9 (77.8–94.8) |
| SD Bioline Dengue Duo (2nd Generation) | Wang and Sekaran [21] | 2010 | Malaysia | 1–15 days | Virus isolation, RT-PCR, rising titer in a paired samples using MAC ELISA | IgM | 53.5 | 100 | Blacksell et al. [19] | 2011 | Sri Lanka | Median 5; IQR 2–7 days illness | AFRIMS MAC and GAC-ELISA paired samples | IgM | 79.2 (70.5–87.2) | 89.4 (83.5–93.7) |
| Panbio Dengue Duo cassette | Blacksell et al. [6] | 2006 | Thailand | Admission | AFRIMS MAC and GAC-ELISA paired samples | IgM | 65.3 (59.9–70.5) | 97.6 (93.9–99.3) |
Nga et al. [32] | 2007 | Vietnam | 3 weeks illness | Focus IgM/IgG ELISA | IgM | 67.3 (57.8–75.6) | 91.7 (84.4–95.7) | IgG | 66.4 (58.4–73.6) | 94.4 (84.9–98.1) |
Moorthy et al. [33] | 2009 | South India | Not stated | Panbio MAC and GAC-ELISA | IgM | 81.8 | 75.0 | IgG | 87.5 | 66.6 | Blacksell et al. [19] | 2011 | Sri Lanka | Median 5; IQR 2–7 days illness |
AFRIMS MAC and GAC-ELISA paired samples | IgM | 70.7 (60.7–79.4) | 80.0 (73.0–85.9) |
| Merlin IgM | Blacksell et al. [19] | 2011 | Sri Lanka | Median 5; IQR 2–7 days illness | AFRIMS MAC and GAC-ELISA paired samples | IgM | 72.7 (62.9–81.2) | 73.8 (66.2–80.4) |
| Biosynex IgM | Blacksell et al. [19] | 2011 | Sri Lanka | Median 5; IQR 2–7 days illness | AFRIMS MAC and GAC-ELISA paired samples | IgM | 79.8 (70.5–87.2) | 46.3 (38.3–54.3) |
| MP Diagnostics ASSURE | Tan et al. [34] | 2011 | Singapore | Acute | NS1 Ag and MAC ELISAs | IgA | 86.7 | 86.1 | Ahmed et al. [35] | 2010 | Bangladesh | Acute and Convalescent | NS1 Ag and MAC ELISAs | IgA | 99.4 | 100 |
|
|